타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tremfya (guselkumab) |
Overview Company | Johnson & Johnson |
Overview Modality | ANTIBODY |
Overview Target | IL-23 p19 |
Overview Indication | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. |
Positioning Known limitation | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. |
Positioning Development positioning | 1L–2L biologic across dermatology, rheumatology, and gastroenterology |
MoA Mechanism | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. |
MoA Biomarker | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. |
Toxicology Species | Pig |
Toxicology Major finding | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Toxicology CRS | N/A |
Clinical Safety signal | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tremfya (guselkumab) |
Overview Company | Johnson & Johnson |
Overview Modality | ANTIBODY |
Overview Target | IL-23 p19 |
Overview Indication | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. |
Positioning Known limitation | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. |
Positioning Development positioning | 1L–2L biologic across dermatology, rheumatology, and gastroenterology |
MoA Mechanism | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. |
MoA Biomarker | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. |
Toxicology Species | Pig |
Toxicology Major finding | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Toxicology CRS | N/A |
Clinical Safety signal | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교